The Institute for In Vitro Sciences, Inc. (IIVS) has received a grant from the Research Institute for Fragrance Materials (RIFM) to support its mission to promote non-animal methods. The grant will be used to purchase equipment that will enable IIVS to expand capabilities and offer several non-animal tests in compliance with Good Laboratory Practices.
IIVS is a non-profit organization based in Gaithersburg, Maryland, wholly dedicated to the promotion of non-animal test methods. Founded in 1997, IIVS is recognized as a leading provider of in vitro testing in support of toxicological safety evaluations. Rigorous scientific programs coupled with educational and outreach initiatives have established IIVS as a global leader in the advancement of alternatives to animal testing.
Established in 1966, based in Woodcliff Lake, New Jersey, the Research Institute for Fragrance Materials, Inc. (RIFM) generates, analyzes, evaluates, and distributes data to provide a scientific basis for the safe use of fragrances. RIFM has compiled the most comprehensive, worldwide source of toxicology data, literature, and general information on fragrance and flavor raw materials — over 70,000 references and more than 135,000 human health and environmental studies.
RIFM’s science staff of 30 full-time professionals conducts safety assessments on fragrance ingredients and undertakes research to support the development of improved assessment methodologies. RIFM has been studying and evaluating fragrance ingredients since its foundation, publishing peer-reviewed safety monographs and group summaries on fragrance ingredients.
“RIFM and IIVS have a long history of working together to identify non-animal testing approaches for fragrance materials.” … “The donation will help us expand our capabilities in photosafety as well as support our growing in vitro skin sensitization program.” – Erin Hill, President of IIVS
“We appreciate IIVS’ commitment to quality non-animal testing which enables RIFM and its member companies to reduce reliance on animal testing for many endpoints.” – Anne Marie Api, Vice President, Human Health Sciences at RIFM.